Published in Acta Pharmacol Sin on May 29, 2017
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36
Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med (1972) 3.98
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed (2008) 3.44
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol (2013) 1.87
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry (2011) 1.53
Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit (1995) 1.28
Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med (1978) 1.22
Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther (2002) 1.21
Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol (2006) 1.19
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol (2011) 1.18
Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol (1976) 1.12
Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl (2003) 1.11
Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm (1993) 1.09
Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? Clin Pharmacokinet (2016) 1.04
Heart disease in myasthenia gravis. Acta Neurol Scand (1984) 1.01
Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci (2007) 0.95
Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharmacol Ther (1980) 0.92
REACTIONS OF CYANATE WITH FUNCTIONAL GROUPS OF PROTEINS. II. FORMATION, DECOMPOSITION, AND PROPERTIES OF N-CARBAMYLIMIDAZOLE. Biochemistry (1965) 0.91
The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord (2015) 0.86
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors? Liver Int (2013) 0.83
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol (2016) 0.79
Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses. AAPS J (2015) 0.78